Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kurt Evans"'
Autor:
Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with chemotherapy in ER+ br
Externí odkaz:
https://doaj.org/article/c251cacd8a6e4763988dbd3811b83598
Autor:
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0195932 (2018)
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient surviva
Externí odkaz:
https://doaj.org/article/d119af3c583145e6b621239e41d5051c
Autor:
Funda Meric-Bernstam, Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt Evans, Erkan Yuca, Stephen Scott, Bryce Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick Ng, Tiimothy DiPeri, Gordon Mills, Jordi Rodon, Senthil Damodaran
The role of the fibroblast growth factor receptor (FGFR) gene alterations as therapeutic targets in breast cancer have not been well characterized. Futibatinib (TAS-120; Taiho) is a novel pan-FGFR inhibitor. We sought to determine the efficacy of fut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a9a4745eb75f67b68818b067517cb40
https://doi.org/10.21203/rs.3.rs-2248209/v1
https://doi.org/10.21203/rs.3.rs-2248209/v1
Autor:
Kaushik Varadarajan, Christian X. Pico, Kurt Evans, Maria G. Raso, Yasmeen Rizvi, Xiaofeng Zheng, Timothy P. Diperi, Bailiang Wang, Stephen Scott, Ming Zhao, Argun Akcakanat, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 83:6180-6180
Introduction: The ataxia telangiectasia and RAD3-related (ATR) kinase is a key component of the DNA damage response (DDR) and functions in conjunction with ataxia telangiectasia mutated (ATM). ATM loss or functional deficiency may enhance reliance on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c591e92445053c31702686585fa6d45c
https://doi.org/10.1158/1538-7445.am2023-6180
https://doi.org/10.1158/1538-7445.am2023-6180
Autor:
Erkan Yuca, Kurt Evans, Argun Akcakanat, Gabriela Raso, Yasmeen Q. Rizvi, Fei Yang, Lauren Byers, Senthil Damodaran, Okajima Daisuke, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 82:1768-1768
Background: Trophoblast cell surface antigen (TROP2), is expressed on many tumors including breast cancer, thus TROP2 antibody drug conjugates are being pursued as a therapeutic strategy. Datopotamab deruxtecan (Dato-DXd) is composed of a humanized a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50f84da935cbd60269c986601f72107c
https://doi.org/10.1158/1538-7445.am2022-1768
https://doi.org/10.1158/1538-7445.am2022-1768
Autor:
Ming Zhao, Timothy P. DiPeri, Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng, Kurt Evans, Argun Akcakanat, Fei Yang, Debu Tripathy, Ecaterina Ileana Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 82:1791-1791
Purpose: TROP2 is overexpressed in many tumor types and is being actively pursued as a target. Sacituzumab govitecan (SG), a humanized anti-TROP2 antibody conjugated with SN-38, was approved for treatment of metastatic triple negative breast cancer,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e96bab1d967fe936e5257722a6ad9fe
https://doi.org/10.1158/1538-7445.am2022-1791
https://doi.org/10.1158/1538-7445.am2022-1791
Autor:
Christian X. Cruz Pico, Dali Li, Christopher D. Lanier, Kurt Evans, Maria G. Raso, Timothy DiPeri, Yasmeen Rizvi, Min Jin Ha, Huiqin Chen, Ming Zhao, Argun Akcakanat, Xiaofeng Zheng, Gokce Toruner, Erkan Yuca, Stephen Scott, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam
Publikováno v:
Molecular Cancer Therapeutics. 20:P058-P058
Introduction: The ATR (ataxia-telangiectasia and Rad3 related protein) kinase inhibitor BAY 1895344 is currently in clinical development for the treatment of advanced solid tumors and has demonstrated promising antitumor activity in heavily pretreate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442ed316544d996f09e88f72041b7684
https://doi.org/10.1158/1535-7163.targ-21-p058
https://doi.org/10.1158/1535-7163.targ-21-p058
Autor:
Roy C. Willis, Xingwang Fang, Weiwei Xu, Angela Burrell, Kurt Evans, Quoc Hoang, Mangkey Bounpheng
Publikováno v:
JALA: Journal of the Association for Laboratory Automation. 12:195-201
We describe automated nucleic acid (NA) isolation from diverse sample types using MagMAX kits (Ambion, Inc.) on KingFisher Magnetic Particle Processors (Thermo Scientific). The MagMAX-96 Blood RNA Isolation Kit is designed for total RNA isolation fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a661ff7fc1ca1dbf6b134b3e6cd1cb9
https://doi.org/10.1016/j.jala.2007.05.001
https://doi.org/10.1016/j.jala.2007.05.001
Autor:
Kurt Evans, Weiwei Xu, Quoc Hoang, Xingwang Fang, Roy C. Willis, Angela Burrell, Sharmili Moturi, Mangkey Bounpheng
Publikováno v:
JALA: Journal of the Association for Laboratory Automation. 11:381-386
Whole blood is an attractive sample source for nucleic acid-based assays because it is readily available, easily accessible, and rich in genetic information. However, globin mRNA accounts for up to 70% of the mRNA (by mass) in whole blood total RNA,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77169c604c8cdbf9467d967815af6029
https://doi.org/10.1016/j.jala.2006.10.001
https://doi.org/10.1016/j.jala.2006.10.001
Publikováno v:
37th Joint Propulsion Conference and Exhibit.
The purpose of the ODC Elimination Program of the Space Shuttle RSRM Program is to eliminate the usage of 1, 1, 1 trichloroethane (TCA) in all RSRM (Reusable Solid Rocket Motor) manufacturing processes. This program consists of the following phases a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51db36e72fd963eae54863999353075a
https://doi.org/10.2514/6.2001-3859
https://doi.org/10.2514/6.2001-3859